<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79501">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070484</url>
  </required_header>
  <id_info>
    <org_study_id>OH2-13-0034</org_study_id>
    <nct_id>NCT02070484</nct_id>
  </id_info>
  <brief_title>Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease</brief_title>
  <official_title>Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OhioHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NuTech Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OhioHealth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect and safety of NuCel to DBX on patients
      undergoing posteriolateral lumbar spinal fusions for degenerative disc disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lumbar Degenerative Disc Disease</condition>
  <condition>Spinal Stenosis</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Spondylosis</condition>
  <condition>Intervertebral Disk Displacement</condition>
  <condition>Intervertebral Disk Degeneration</condition>
  <condition>Spinal Diseases</condition>
  <condition>Bone Diseases</condition>
  <condition>Musculoskeletal Diseases</condition>
  <condition>Spondylolysis</condition>
  <arm_group>
    <arm_group_label>NuCel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stemcell allograft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DBM bone graft substitute</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NuCel</intervention_name>
    <arm_group_label>NuCel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Deminaralized Bone Matrix</intervention_name>
    <arm_group_label>DBX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 75 years

          -  Symptomatic, single-level degenerative lumbar disc disease, spondylosis or
             spondylolisthesis

          -  Failed conservative treatments

          -  Low risk for non-union

          -  Must be candidates for single-level, posteriolateral lumbar spine fusion

          -  Must be able and willing to give Informed Consent

          -  English-speaking

        Exclusion Criteria:

          -  Smoker (any smoking â‰¤3 months prior to consent); (Patel et al. 2013)

          -  Patients with poorly controlled diabetes mellitus (HgbA1c &gt; 7%)

          -  Documented osteoporosis

          -  Prior lumbar spinal surgery at the same spinal level, or immediately adjacent spine
             level, to the level being operated on

          -  Back pain due to infection, tumour, or metabolic bone disease

          -  Terminal disease, such as HIV infection, neoplasm

          -  Autoimmune disease, such as rheumatoid arthritis

          -  Morbid obesity (body mass index (BMI) of 35 kg/m2)

          -  Major psychiatric illness in the last year

          -  History of alcohol or drug abuse in the last year

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Shehadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OhioHealth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 13, 2016</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OhioHealth</investigator_affiliation>
    <investigator_full_name>Joseph A. Shehadi, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NuCel</keyword>
  <keyword>Lumbar Spine</keyword>
  <keyword>Degenerative Disease</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Intervertebral Disc Displacement</mesh_term>
    <mesh_term>Spondylosis</mesh_term>
    <mesh_term>Spondylolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
